Jim Cramer: Bristol-Myers Needs to Slim Down
Bristol-Myers Squibb needs to reorganize itself in what is now a challenging environment, says Jim Cramer.
Bristol-Myers Squibb (BMY) - Get Report is being viewed as a pharmaceutical company again, TheStreet's Jim Cramer said -- not a rapidly growing biotech. That means the company needs to restructure itself, he commented.
